Associate Professor of Health Economics at the University of Exeter Medical School, Anne has over 20 years’ experience of leading health economic evaluations of clinical trials and research into the measurement and valuation of health. She also has over 11 years’ experience of teaching Health Economics and Microeconomics, and has co-authored a Health Economics book, ‘Economic Analysis in Health Care’ (Wiley, 2012).
Anne currently co-leads the Cancer Research UK funded project to measure the impact of the NICE 2015 suspected cancer guidelines on times to diagnosis, stage at diagnosis, treatment with curative intent and survival. She is also co-investigator on the NIHR Health Technology Assessment Programme funded Aids to Cancer Diagnosis in Primary Care.
Anne is known internationally for her research around decision making and methodology around preference elicitation. She has pioneered the calculation of Quality Adjusted Life Years (QALYs) within discrete choice experiments using risk and motivated current research that looks at revaluing the EQ-5D 5L scale.
Anne has expertise in decision analytic models to extrapolate the findings of trial based analyses. She also led the Health Economics work stream of the NeoNet 1 and NeoNet 2 projects funded by NIHR Health Services and Delivery Research Programme to evaluate the cost effectiveness of alternative configurations of neonatal services in England.
+44 (0)1392 726441
University of Exeter, UK
- Multi-parametric magnetic resonance imaging (mpMRI) for prostate cancer diagnosis in primary care
- What is the clinical-effectiveness and cost-effectiveness of embedded risk-of-cancer assessment of patients in primary care; the ERICA trial
- Evaluating the impact of NICE guidelines for suspected cancers in respect of diagnostic interval and other outcomes
- Aids to cancer diagnosis in primary care
- Exploring patient, practitioner and general population preferences towards diagnostic tests for cancer
- CanTest Network Analysis
- Exploring the complex relationships between pre-existing conditions and cancer diagnosis in an ageing population (PhD)
- Understanding and implementing artificial intelligence technologies to improve skin cancer assessment in primary care settings (PhD)
- The economics of cancer: Evaluation of the equity and efficiency trade-offs in colorectal, lung and ovarian cancer (PhD)
- SPOtting Cancer among Comorbidities (SPOCC) programme: Supporting clinical decision making in patients with symptoms of cancer and pre-existing conditions
- Walter FM, Thompson MJ, Wellwood I, Abel GA, Hamilton W, Johnson M, Lyratzopoulos G, Messenger MP, Neal RD, Rubin G, Singh H, Spencer A, Sutton S, Vedstead P, Emery JD. Evaluating diagnostic strategies for early detection of cancer: the CanTest framework. BMC Cancer, 2019, 19:586
- Price S, Zhang X, Spencer A. Measuring the impact of national guidelines: What methods can be used to uncover time-varying effects for healthcare evaluations? Social Science and Medicine, 2020, 258(113021), doi: 10.1016/j.socscimed.2020.113021
- Price S, Spencer A, Zhang X, Ball S, Lyratzopoulos, Mujica-Mota R, Stapley S, Ukoumunne OC, Hamilton W. Trends in time to cancer diagnosis around the period of changing national guidance on referral of symptomatic patients: A serial cross-sectional study using UK electronic healthcare records from 2006–17. Cancer Epidemiology, 2020; 101805, doi: 10.1016/j.canep.2020.101805
- Ward T, Medina-Lara A, Mujica-Mota RE, Spencer AE. Accounting for Heterogeneity in Resource Allocation Decisions: Methods and Practice in UK Cancer Technology Appraisals. Value Health, 2021; Jul;24(7):995-1008. doi: 10.1016/j.jval.2020.12.022.
- Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, Hamilton W. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med 20, 54 (2022). doi: 10.1186/s12916-021-02230-y
- Hall R, Medina-Lara A, Hamilton W, Spencer A. Attributes Used for Cancer Screening Discrete Choice Experiments: A Systematic Review. Patient (2021). doi: 10.1007/s40271-021-00559-3
- Hall R, Medina-Lara A, Hamilton W, Spencer A. Correction to: Attributes Used for Cancer Screening Discrete Choice Experiments: A Systematic Review. Patient (2021). doi: 10.1007/s40271-021-00562-8
- Hall R, Medina-Lara A, Hamilton W, Spencer A. Women’s priorities towards ovarian cancer testing: a best–worst scaling study. BMJ Open (2022); 12:e061625. doi: 10.1136/bmjopen-2022-061625
- Price S, Landa P, Mujica-Mota R, Hamilton W, Spencer A. Revising the Suspected-Cancer Guidelines: Impacts on Patients’ Primary Care Contacts and Costs. Value in Health, Aug 2022.